Antimicrobial Resistance is Rising
π
0
deaths / year by 2050
(The Lancet 2022; O'Neill Report 2016)
π°
$0
cumulative loss by 2050
(O'Neill Report 2016; World Bank 2017)
Conventional antibiotics are failing
Resistance fuels transmission
Resistant infections spread 2β3Γ faster π
(The Lancet 2013)
10% of post-surgical infections are resistant π₯
(ESPAUR Report 2023)
"Resist and spread"
The ESKAPE Pathogens
Together, they represent the leading cause of hospital-acquired infections worldwide β escaping most conventional antibiotics and spreading rapidly across settings.
Hospital infections (ESKAPE)
~60%
Global cases / year
>2M
Mortality rate
~25%
Among the ESKAPE group, MRSA, Methicillin-Resistant Staphylococcus aureus, is the most prevalent and widely transmitted pathogen.
MRSA
Methicillin-Resistant Staphylococcus aureus
The Superbug
Global MRSA infections (2019):
~150 million
~150 million
mecA β PBP2a β Ξ²-lactam resistance
mecA encodes PBP2a with low Ξ²-lactam affinity,
enabling MRSA to keep cell-wall synthesis under drug pressure.
Our goal is to overcome resistant and transmissible pathogens.
MRSA serves as our model organism.
FoCas
A Novel Antimicrobial-Resistance Treatment and Infectivity Inhibition Platform
[Fo] Delivery System: DNA Origami
[Cas] Gene Editing System: CRISPR-Cas9
Targeted Knockout of the MRSA Resistance Gene mecA
Four Functional Component
Five Acting Module
Application: MRSA Wound Infection
Method of Administration: Hydrogel or Spray
Simple Procedure of FoCas Acting as A Universal Platform
Programmable Modular Scalable
Assembly-Design-Administration
FoCas redefines how we fight superbugs.
Promotion Video
